PDF(Pubmed)
Abstract：
BACKGROUND: Despite the availability of vaccination, TBE (tick-borne encephalitis) remains a global public health problem. Therefore, the aim of our study was to assess the long-term efficacy of vaccinations against tick-borne encephalitis using vaccines available on the European market.
METHODS: The analysis was conducted on the results of a systematic review conducted in accordance with the Cochrane Handbook for Systematic Reviews of Interventions. The search was performed in three databases, namely Medline (via PubMed), EMBASE (via Ovid), and the Cochrane Library database. The authors followed the PRISMA method and the selection of the articles was performed with two independent researchers.
RESULTS: From a total of 199 citations, 9 studies were included in this review. According to the primary studies identified in the search, the efficacy of available anti-TBE vaccines ranges from 90.1% to 98.9%; however, in individuals above the age of 60, the protection wanes as early as one year after vaccination. Administration of a booster dose 3 years after completion of the basic vaccination schedule significantly extended the period of protection against TBE.
CONCLUSIONS: Anti-TBE vaccines available in Europe have a high level of efficacy. However, the level of protection against TBE is decreasing after vaccination. Therefore, in addition to the conventional schedule, booster vaccines should be administered every 5 years in individuals before the age of 60 and more frequently, e.g. every 3 years, in individuals aged 60 and beyond.
METHODS: The analysis was conducted on the results of a systematic review conducted in accordance with the Cochrane Handbook for Systematic Reviews of Interventions. The search was performed in three databases, namely Medline (via PubMed), EMBASE (via Ovid), and the Cochrane Library database. The authors followed the PRISMA method and the selection of the articles was performed with two independent researchers.
RESULTS: From a total of 199 citations, 9 studies were included in this review. According to the primary studies identified in the search, the efficacy of available anti-TBE vaccines ranges from 90.1% to 98.9%; however, in individuals above the age of 60, the protection wanes as early as one year after vaccination. Administration of a booster dose 3 years after completion of the basic vaccination schedule significantly extended the period of protection against TBE.
CONCLUSIONS: Anti-TBE vaccines available in Europe have a high level of efficacy. However, the level of protection against TBE is decreasing after vaccination. Therefore, in addition to the conventional schedule, booster vaccines should be administered every 5 years in individuals before the age of 60 and more frequently, e.g. every 3 years, in individuals aged 60 and beyond.
摘要：
背景：尽管有疫苗接种，TBE（蜱传脑炎）仍然是一个全球性的公共卫生问题。因此,我们研究的目的是评估使用欧洲市场上的疫苗接种预防蜱传脑炎的长期疗效.
方法：分析是根据《Cochrane干预措施系统评价手册》进行的系统评价结果进行的。在三个数据库中进行了搜索，即Medline(通过PubMed)，EMBASE（通过Ovid），和Cochrane图书馆数据库.作者遵循PRISMA方法，并由两名独立研究人员进行文章的选择。
结果：在总共199篇引文中，本综述包括9项研究。根据搜索中确定的主要研究，可用的抗TBE疫苗的效力范围为90.1%至98.9%；然而，在60岁以上的人群中，这种保护最早在接种疫苗后一年就消失了。在基本疫苗接种时间表完成后3年施用加强剂量显著延长了针对TBE的保护期。
结论：欧洲可获得的抗TBE疫苗具有高水平的效力。然而,疫苗接种后,对TBE的保护水平正在下降.因此,除了常规的时间表，加强疫苗应每5年对60岁之前的个体进行一次，并且更频繁地进行，例如，每3年，60岁及以上的人。
方法：分析是根据《Cochrane干预措施系统评价手册》进行的系统评价结果进行的。在三个数据库中进行了搜索，即Medline(通过PubMed)，EMBASE（通过Ovid），和Cochrane图书馆数据库.作者遵循PRISMA方法，并由两名独立研究人员进行文章的选择。
结果：在总共199篇引文中，本综述包括9项研究。根据搜索中确定的主要研究，可用的抗TBE疫苗的效力范围为90.1%至98.9%；然而，在60岁以上的人群中，这种保护最早在接种疫苗后一年就消失了。在基本疫苗接种时间表完成后3年施用加强剂量显著延长了针对TBE的保护期。
结论：欧洲可获得的抗TBE疫苗具有高水平的效力。然而,疫苗接种后,对TBE的保护水平正在下降.因此,除了常规的时间表，加强疫苗应每5年对60岁之前的个体进行一次，并且更频繁地进行，例如，每3年，60岁及以上的人。
